CENTOGENE N.V. (CNTG): Price and Financial Metrics

CENTOGENE N.V. (CNTG): $0.38

0.01 (+2.74%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

C

CNTG Price/Volume Stats

Current price $0.38 52-week high $1.98
Prev. close $0.37 52-week low $0.34
Day low $0.36 Volume 48,800
Day high $0.39 Avg. volume 102,436
50-day MA $0.45 Dividend yield N/A
200-day MA $0.91 Market Cap 10.16M

CNTG Stock Price Chart Interactive Chart >


CENTOGENE N.V. (CNTG) Company Bio


Centogene NV is a commercial-stage company. It focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. It operates through the following two segments: Pharmaceutical and Diagnostics. The Pharmaceutical segment provides services to pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery and patient monitoring. The Diagnostics segment provides targeted genetic sequencing and diagnostics services. The company was founded by Arndt Rolf and Christoph Ehlers in 2006 and is headquartered in Rostock, Denmark.


CNTG Latest News Stream


Event/Time News Detail
Loading, please wait...

CNTG Latest Social Stream


Loading social stream, please wait...

View Full CNTG Social Stream

Latest CNTG News From Around the Web

Below are the latest news stories about CENTOGENE NV that investors may wish to consider to help them evaluate CNTG as an investment opportunity.

CENTOGENE Announces Voting Results of Extraordinary General Meeting

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the voting results of the Company’s Extraordinary General Meeting. All voting items on the agenda, which included the adoption of Dutch statutory annual accounts for the financial year ended December 31, 2022, were passed by the requisite majority. Peer Schatz, Chairman

Yahoo | December 19, 2023

CENTOGENE’s Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the Company reached its initial recruitment and genetic testing milestone in the observational EFRONT Study, being conducted to advance the genetic understanding of frontotemporal dementia (FTD). The EFRONT Study has been conducted with support from Alector, a clinical

Yahoo | December 13, 2023

CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture Transaction

Lifera Omics, newly formed Joint Venture (JV) to be based in Riyadh, Saudi Arabia, provides state-of-the-art genomic and multiomic testing services to patients, health systems, biopharma clients, and research institutions across the Gulf Cooperation Council (GCC) region CENTOGENE to receive an additional $10 million upfront JV milestone payment, following an initial $30 million investment from Lifera. Company eligible for additional performance-related milestone payments and revenue-based royalt

Yahoo | November 28, 2023

CENTOGENE, University College London, and Global Team of Researchers Discover Gene Associated With New Neurodevelopmental Disease Linked to Early-Onset Dystonia and Parkinsonism

Results From Landmark Study Published in Brain JournalCollaborative research initiative leveraged CENTOGENE’s Whole Exome Sequencing (WES) to reveal disease-causing gene called ACBD6 (Acyl-CoA Binding Domain Containing 6) Over seven years, a total of 45 affected individuals from 29 independent families in Southeast Asia, Central Asia, the Middle East, Europe, and North and South America have been identified Study guides further research for potential treatments, including genetic causes and path

Yahoo | November 14, 2023

CENTOGENE Expands Multiomic Diagnostic Portfolio With Newly-Launched Transcriptomic Offering

Incorporating RNA sequencing provides better diagnostics to enable a more complete understanding of disease biologyCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the expansion of MOx, the Company’s multiomic diagnostic portfolio, now incorporating cutting-edge transcriptomic analysis. CENTOGENE’s MOx 2.0 is a single

Yahoo | October 10, 2023

Read More 'CNTG' Stories Here

CNTG Price Returns

1-mo -9.55%
3-mo -45.71%
6-mo -67.24%
1-year -53.37%
3-year -96.40%
5-year N/A
YTD -68.33%
2023 29.03%
2022 -82.21%
2021 -51.50%
2020 7.05%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!